Zobrazeno 1 - 10
of 142
pro vyhledávání: ''
Autor:
Efthymia Skafida, Meletios-Athanasios Dimopoulos, Kleoniki Apostolidou, Angeliki Rouvalis, Garyfallia Bletsa, Maria Kaparelou, Angeliki Andrikopoulou, F. Zagouri, Konstantinos Koutsoukos, Michalis Liontos
Publikováno v:
International Journal of Gynecologic Cancer. 33:571-576
Background: Immune checkpoint inhibitors (ICIs) have been widely implemented in the treatment of solid tumors. Although epithelial ovarian carcinoma is considered as scarcely immunogenic, the presence of tumor-infiltrating T lymphocytes (TILs) in the
Publikováno v:
International Journal of Gynecologic Cancer. 31:1165-1174
The incidence and mortality rates from endometrial cancer continue to increase worldwide, while rates in most other cancers have either plateaued or declined considerably. Uterine serous carcinoma represents a fraction of all endometrial malignancies
Publikováno v:
International Journal of Gynecologic Cancer. 31:824-828
ObjectiveIn this study we investigated response rates of bevacizumab in addition to weekly paclitaxel and carboplatin in neoadjuvant setting in cervical cancer stage IB–IIB.MethodsIn this retrospective study we included patients with FIGO 2018 stag
Autor:
Edison Gilberto Ardila, Daniel Sanabria, F. Heredia, Javier Burbano, David Viveros-Carreño, Juliana Rodriguez
Publikováno v:
International Journal of Gynecologic Cancer. 31:387-398
BackgroundManagement of cervical cancer tumors >2 cm has been a subject of controversy, with management often considered as either up-front radical trachelectomy or neoadjuvant chemotherapy before fertility-sparing surgery.MethodsA systematic literat
Autor:
Hee Seung Kim, Hyunhoon Chung, Se Ik Kim, Eun Ji Lee, Maria Lee, Jae Weon Kim, Yong Sang Song, Noh Hyun Park
Publikováno v:
International Journal of Gynecologic Cancer. 30:1943-1950
ObjectiveEvidence on recurrence patterns after bevacizumab in epithelial ovarian cancer is still insufficient. The aim of this study was to evaluate recurrence patterns after treatment with bevacizumab as second-line treatment in patients with platin
Autor:
Anca Chelariu-Raicu, John J. Kavanagh, Brian M. Slomovitz, Robert L. Coleman, Christopher Morrison, Diane C. Bodurka, Judith K. Wolf, David M. Gershenson, Charles F Levenback
Publikováno v:
International Journal of Gynecologic Cancer. 30:1768-1774
Introduction50–70% of epithelial ovarian cancers overexpress epidermal growth factor receptor, and its expression has been correlated with poor prognosis. We conducted a phase Ib/II trial to examine the efficacy, safety, and toxicity of gefitinib,
Publikováno v:
International Journal of Gynecologic Cancer. 30:1576-1582
IntroductionWe aimed to evaluate poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) regimens in BRCA-mutated ovarian cancer for patients responsive to front-line platinum (bevacizumab and olaparib, veliparib and chemotherapy, olaparib) or platinum
Autor:
Alexander Burges, Christian Kurzeder, Frederik Marmé, Florian Heitz, Andrés Redondo, Kristina Lindemann, Domenica Lorusso, Patricia Pautier, Nadin Cron, Pauline Wimberger, Jonathan A. Ledermann, Philipp Harter, Xavier Paoletti, Edgar Petru, Jalid Sehouli, Alexander Reuss, Nikolaus Degregorio, Els Van Nieuwenhuysen
Publikováno v:
International Journal of Gynecologic Cancer. 30:1997-2001
BackgroundImprovement in clinical outcomes of patients with platinum-resistant disease is an unmet medical need and trials in this population are urgently needed. Checkpoint-inhibitors have already shown activity in multiple other tumor entities and
Autor:
Antonio Casado, Helen Hatcher, Manon Huizing, Dan Stark, Isabelle Ray-Coquard, Nick Reed, Sarah Pratap, Barbara Hermes, Beatrice Seddon, Nicolas Isambert, Lars H. Lindner, Claudia Valverde, Paolo G. Casali, Anjana Anand, Robin L. Jones, Corneel Coens, Anne Floquet, Annekke Westermann, Emmanuelle Bompas
Publikováno v:
International journal of gynecological cancer, 30(10), 1633-1637. Wolters Kluwer Health
International journal of gynecological cancer
International journal of gynecological cancer
Funder: European Organisation for Research and Treatment of Cancer; FundRef: http://dx.doi.org/10.13039/501100004897
Funder: Ligue Nationale de Lutte contre le Cancer (France)
BACKGROUND: Uterine sarcomas are a group of rare tumors that inc
Funder: Ligue Nationale de Lutte contre le Cancer (France)
BACKGROUND: Uterine sarcomas are a group of rare tumors that inc
Autor:
Elise B. Morocco, Begüm Özel, Koji Matsuo, Christina E. Dancz, Marcia A. Ciccone, Mahdi Khoshchehreh, Lynda D. Roman, Heena Pursuwani, Rachel S. Mandelbaum, Richard J. Paulson, Shinya Matsuzaki
Publikováno v:
International Journal of Gynecologic Cancer. 30:1-9
IntroductionPrevious studies have suggested that metformin use may enhance the therapeutic effect of progestin therapy for endometrial hyperplasia or malignancy. However, it is not known how the impact of concurrent metformin may be altered by route